Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067629 | 0.89 | GAA (0.49) | KMT2AMEN1RAB9ARECQLMAPK1 | |
| SCHEMBL3074720 | 0.89 | TSHR (0.49) | KMT2AMEN1RAB9ARECQLMAPK1 | |
| SCHEMBL4599192 | 0.82 | TSHR (0.44) | KMT2AMEN1RAB9ARECQLMAPK1 | |
| SCHEMBL3067393 | 0.82 | GAA (0.47) | KMT2AMEN1RAB9ARECQLMAPK1 | |
| SCHEMBL3078730 | 0.82 | KMT2A (0.44) | KMT2AMEN1RAB9ARECQLMAPK1 | |
| SCHEMBL3069707 | 0.82 | GAA (0.47) | KMT2AMEN1RAB9ARECQLMAPK1 | |
| SCHEMBL4599063 | 0.76 | TSHR (0.43) | KMT2AMEN1RAB9AMAPK1TSHR | |
| SCHEMBL4599609 | 0.76 | TSHR (0.43) | KMT2AMEN1RAB9AMAPK1TSHR | |
| SCHEMBL3075235 | 0.76 | TSHR (0.54) | KMT2AMEN1RAB9AMAPK1TSHR | |
| SCHEMBL3067877 | 0.74 | ATM (0.59) | KMT2AMEN1RAB9AMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222217-A1 | Fungicidal N-[2-(Haloalkoxy)Phenyl]Heteroarylcarboxamides | BASF AKTIENGESELLSCHAFT (DE) | 2010-09-02 | — | — | US | claimed |
| US-20080255107-A1 | Fungicidal Mixtures Comprising N-[2-(Haloalk(Enyl)Oxy)Phenyl]Carboxamides | BASF SE (DE) | 2008-10-16 | — | — | US | claimed |
| EP-1912497-A1 | FUNGICIDAL N-[2-(HALOALKOXY)PHENYL]HETEROARYLCARBOXAMIDES | BASF SE (DE) | 2008-04-23 | — | — | EP | claimed |
| WO-2007017450-A1 | FUNGICIDAL N-[2-(HALOALKOXY)PHENYL]HETEROARYLCARBOXAMIDES | BASF SE (DE) | 2007-02-15 | — | — | WO | claimed |
| US-20100222217-A1 | Fungicidal N-[2-(Haloalkoxy)Phenyl]Heteroarylcarboxamides | BASF AKTIENGESELLSCHAFT (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20080255107-A1 | Fungicidal Mixtures Comprising N-[2-(Haloalk(Enyl)Oxy)Phenyl]Carboxamides | BASF SE (DE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255107-A1 | Fungicidal Mixtures Comprising N-[2-(Haloalk(Enyl)Oxy)Phenyl]Carboxamides | CBR3, CBR1, NAT1 | KMT2A 3199/4885MEN1 3594/4885RAB9A 3399/4885 |
| US-20100222217-A1 | Fungicidal N-[2-(Haloalkoxy)Phenyl]Heteroarylcarboxamides | CBR3, HDHD5, CYP8B1 | KMT2A 1434/4885MEN1 3551/4885RAB9A 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.